Alisporivir

Alisporivir is an experimental drug that was initially developed for the treatment of Hepatitis C. It is a non-immunosuppressive derivative of Cyclosporin A, a drug commonly used in organ transplantation. Alisporivir is a host-targeting antiviral, meaning it works by boosting the body's natural defenses against viruses, rather than directly attacking the virus itself.

History[edit | edit source]

Alisporivir was developed by the Swiss pharmaceutical company Novartis. In 2012, the drug was in Phase III clinical trials for the treatment of Hepatitis C. However, the trials were halted due to safety concerns. Despite this setback, research into the potential uses of Alisporivir continues.

Mechanism of Action[edit | edit source]

Alisporivir works by inhibiting a protein called cyclophilin, which is essential for the replication of the Hepatitis C virus. By blocking this protein, Alisporivir prevents the virus from multiplying and spreading throughout the body.

Potential Uses[edit | edit source]

While Alisporivir was initially developed for the treatment of Hepatitis C, research suggests it may have potential uses in the treatment of other viral infections, including HIV and Coronavirus.

Safety Concerns[edit | edit source]

In 2012, the Food and Drug Administration (FDA) halted Phase III clinical trials of Alisporivir due to safety concerns. Several patients in the trial developed pancreatitis, a serious and potentially life-threatening inflammation of the pancreas. The FDA has since lifted the hold, but the future of Alisporivir remains uncertain.